1.
Nature
; 441(7091): 282, 2006 May 18.
Article
in English
| MEDLINE
| ID: mdl-16710392
Subject(s)
Antimalarials/administration & dosage , Antimalarials/supply & distribution , Artemisinins/administration & dosage , Artemisinins/supply & distribution , Malaria/drug therapy , Sesquiterpenes/administration & dosage , Sesquiterpenes/supply & distribution , Antimalarials/economics , Antimalarials/therapeutic use , Artemisinins/economics , Artemisinins/therapeutic use , Drug Costs , Drug Resistance , Drug Therapy, Combination , Humans , Malaria/economics , Sesquiterpenes/economics , Sesquiterpenes/therapeutic use
2.
Nat Rev Drug Discov
; 4(11): 878, 2005 Nov.
Article
in English
| MEDLINE
| ID: mdl-16299916
Subject(s)
Drug Industry , Organizations, Nonprofit , Developing Countries , Drug Industry/economics , Drug Industry/organization & administration , Drugs, Investigational , Financial Management , Global Health , Organizations, Nonprofit/economics , Organizations, Nonprofit/organization & administration , Pharmaceutical Preparations/supply & distribution
3.
Health Aff (Millwood)
; 24(4): 1057-63, 2005.
Article
in English
| MEDLINE
| ID: mdl-16012146
ABSTRACT
Although some pharmaceutical company efforts to develop and distribute drugs in developing countries have been successful, many fall short of meeting needs in resource-poor nations. In the context of public-private partnerships, we discuss the concept of a nonprofit pharmaceutical company dedicated to developing and distributing drugs for diseases endemic in developing countries. Using the experience of the Institute for OneWorld Health, we present the vision, core elements of the product development model, and challenges confronting this model. Despite limitations, early successes raise hopes that a nonprofit drug company can exist successfully both as a global health organization and as a business.